The publication of the updated individual patient data meta-analysis of the larger randomised trials of intravenous rt-PA for acute ischaemic stroke has re-opened the debate about how the treatment should be used in routine practice, and what information can be expected to emerge in the next 2-3 years from the ongoing trials [the largest of which is the Third International Stroke Trial (IST-3)].
AD - University of Edinburgh, Edinburgh, UK. peter.sandercock@ed.ac.uk AN - 20854621 BT - International Journal of Stroke ET - 2010/09/22 LA - eng M1 - 5 N1 - Sandercock, PeterWardlaw, JoannaLindley, RichardEnglandInternational journal of stroke : official journal of the International Stroke SocietyInt J Stroke. 2010 Oct;5(5):381-2. N2 -The publication of the updated individual patient data meta-analysis of the larger randomised trials of intravenous rt-PA for acute ischaemic stroke has re-opened the debate about how the treatment should be used in routine practice, and what information can be expected to emerge in the next 2-3 years from the ongoing trials [the largest of which is the Third International Stroke Trial (IST-3)].
PY - 2010 SN - 1747-4949 (Electronic)1747-4930 (Linking) SP - 381 EP - 2 T2 - International Journal of Stroke TI - 'Where are we now with intravenous thrombolysis for acute ischaemic stroke?' VL - 5 ER -